Ophthotech has completed patient enrolment in its Phase IIa clinical trial of Zimura (avacincaptad pegol) in combination with Lucentis (ranibizumab) for treating naïve patients with wet age-related macular degeneration (AMD).
AMD is a medical condition that could lead to blurred or no vision in the centre of the visual field.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The dose-ranging, multi-centre trial includes a total of 64 patients.
The trial aims to evaluate safety at different dosages and to identify a potential efficacy signal.
Data from the trial is expected to be evaluated at month six, while initial top-line data are scheduled to be provided before the end of this year.
Ophthotech chief medical officer Kourous Rezaei said: “Following the completion of this trial, clinical data will be analysed to assess whether to proceed to a randomised, sham controlled clinical trial of Zimura combination therapy in wet AMD.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataZimura (avacincaptad pegol) was developed by Ophthotech as a complement factor C5 inhibitor for treating patients with wet AMD.
Apart from the Phase IIa, Zimura is currently being investigated as monotherapy in a Phase IIb clinical trial for patients with geographic atrophy secondary to dry AMD and in a Phase IIb clinical trial for the prevention of autosomal recessive Stargardt disease (STGD1).
Additionally, Zimura is being analysed as combination therapy with Eylea (aflibercept), an anti-VEGF agent, in patients with idiopathic polypoidal choroidal vasculopathy (IPCV).
Lucentis (ranibizumab) is an anti-vascular endothelial growth factor (anti-VEGF) agent.
